CRF takes over interventional component of ACC conference
The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) have formed a multi-year partnership to jointly sponsor the ACC i2 interventional cardiology meeting in Orlando, Fla., March 28-31, 2009, during ACC.09, the ACC’s 58th scientific session.

This will be the beginning of a five-year partnership committed to collectively developing the interventional component of the ACC annual scientific session, according to ACC and CRF.

The “Innovation in Intervention: i2 Summit in partnership with the Cardiovascular Research Foundation” at ACC.09 in Orlando, will deliver in-depth and cutting-edge science provided in a forum for both general cardiologists and interventional specialists, educating and guiding physicians, as well as cardiac care team members, to the next level of knowledge and practice, the college and the foundation said.

ACC said that the meeting will emphasize the translation of evidence-based science and clinical trial data into daily interventional practice.

"The annual scientific session of the American College of Cardiology represents a unique opportunity to introduce the latest advances in interventional medicine to the greater cardiology community. It is our hope that CRF’s expertise in cutting edge medical education will help appropriately translate evidence-based science into clinical practice,” said Gregg W. Stone, MD, chairman of the CRF and professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital in New York City.

“The i2 Summit will offer unsurpassed evidence-based content, presented by leaders in interventional cardiology, and this collaboration brings together the strengths and expertise of both the ACC and CRF to deliver an unparalleled program that appeals to all cardiovascular professionals,” said ACC President Douglas Weaver, MD. “The ACC is committed to providing more value to attendees at our meeting by having a wide venue of educational opportunities for physicians including state-of-the-art updates, late breaking clinical trials and education required for credentialing and recertification.”